Kazuhiro Matsumoto - Search Results

Year	Number of Results
2002	2
2003	1
2005	2
2006	3
2007	4
2008	5
2009	4
2010	15
2011	14
2012	11
2013	11
2014	13
2015	15
2016	17
2017	12
2018	17
2019	15
2020	20
2021	26
2022	23
2023	21
2024	15

1

Risk factors for postoperative fever after laparoscopic adrenalectomy focusing on hormones produced: a case control study.

Izawa M, Takeda T, Anno T, Iwasawa T, Yasumizu Y, Tanaka N, Matsumoto K, Morita S, Kosaka T, Mizuno R, Asanuma H, Oya M. Izawa M, et al. Among authors: matsumoto k. BMC Urol. 2024 Apr 18;24(1):90. doi: 10.1186/s12894-024-01469-w. BMC Urol. 2024. PMID: 38637748 Free PMC article.

2

Detection of the Highest-Grade Lesion in Multifocal Discordant Prostate Cancer by Multiparametric Magnetic Resonance Imaging.

Matsumoto K, Akita H, Hashiguchi A, Takeda T, Kosaka T, Fukumoto K, Yasumizu Y, Tanaka N, Morita S, Mizuno R, Asanuma H, Oya M, Jinzaki M. Matsumoto K, et al. Clin Genitourin Cancer. 2024 Mar 21;22(3):102084. doi: 10.1016/j.clgc.2024.102084. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 38608334

3

ASO Author Reflections: Vasohibin-1 as a Biomarker for Chemotherapeutic Response in Patients with Advanced Bladder Cancer.

Omura M, Kosaka T, Kobayashi H, Shigeta K, Matsumoto K, Hara S, Kikuchi E, Mikami S, Saya H, Sato Y, Oya M. Omura M, et al. Among authors: matsumoto k. Ann Surg Oncol. 2024 Apr 2. doi: 10.1245/s10434-024-15122-1. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38564070 No abstract available.

4

Factors impacting antibody kinetics, including fever and vaccination intervals, in SARS-CoV-2-naïve adults receiving the first four mRNA COVID-19 vaccine doses.

Matsuura T, Fukushima W, Nakagama Y, Kido Y, Kase T, Kondo K, Kaku N, Matsumoto K, Suita A, Mukai E, Nitahara Y, Konishi A, Kasamatsu A, Nakagama S, Nakagami-Yamaguchi E, Ohfuji S, Kaneko Y, Kaneko A, Kakeya H, Hirota Y. Matsuura T, et al. Among authors: matsumoto k. Sci Rep. 2024 Mar 27;14(1):7217. doi: 10.1038/s41598-024-57931-0. Sci Rep. 2024. PMID: 38538722 Free PMC article.

5

Prediction of pathological up-staging after radical nephroureterectomy in patients with upper tract urothelial carcinoma.

Shojo K, Takeda T, Akita H, Suzuki T, Mikami S, Shigeta K, Yasumizu Y, Tanaka N, Matsumoto K, Morita S, Kosaka T, Mizuno R, Asanuma H, Jinzaki M, Oya M. Shojo K, et al. Among authors: matsumoto k. World J Urol. 2024 Mar 26;42(1):192. doi: 10.1007/s00345-024-04808-6. World J Urol. 2024. PMID: 38530492

6

Vasohibin-1 Expression Can Predict Pathological Complete Remission of Advanced Bladder Cancer with Neoadjuvant Chemotherapy.

Omura M, Kosaka T, Kobayashi H, Shigeta K, Matsumoto K, Hara S, Kikuchi E, Mikami S, Saya H, Sato Y, Oya M. Omura M, et al. Among authors: matsumoto k. Ann Surg Oncol. 2024 May;31(5):2951-2958. doi: 10.1245/s10434-024-15009-1. Epub 2024 Feb 20. Ann Surg Oncol. 2024. PMID: 38376711 Free PMC article.

7

New risk stratification for adjuvant nivolumab for high-risk muscle-invasive urothelial carcinoma.

Saito T, Kanao K, Matsumoto K, Fukumoto K, Igarashi D, Takahashi T, Kaneko G, Shirotake S, Nishimoto K, Mizuno R, Ishida M, Hara S, Oya M, Oyama M. Saito T, et al. Among authors: matsumoto k. BJUI Compass. 2023 Oct 27;5(2):281-288. doi: 10.1002/bco2.298. eCollection 2024 Mar. BJUI Compass. 2023. PMID: 38371203 Free PMC article.

8

Impact of prostatic shape on the difficulty of robot-assisted laparoscopic radical prostatectomy.

Kamisawa K, Matsumoto K, Takeda T, Takamatsu K, Niwa N, Yasumizu Y, Tanaka N, Morita S, Kosaka T, Mizuno R, Asanuma H, Oya M. Kamisawa K, et al. Among authors: matsumoto k. Asian J Endosc Surg. 2024 Apr;17(2):e13291. doi: 10.1111/ases.13291. Asian J Endosc Surg. 2024. PMID: 38355894

9

Unraveling the Mechanism of Cork Spot-like Physiological Disorders in 'Kurenainoyume' Apples Based on Occurrence Location.

Imura E, Nakagomi M, Hayashida T, Fujita T, Sato S, Matsumoto K. Imura E, et al. Among authors: matsumoto k. Plants (Basel). 2024 Jan 27;13(3):381. doi: 10.3390/plants13030381. Plants (Basel). 2024. PMID: 38337914 Free PMC article.

10

Profiling Fibroblast Growth Factor Receptor 3 Expression Based on the Immune Microenvironment in Upper Tract Urothelial Carcinoma.

Shigeta K, Matsumoto K, Kitaoka S, Omura M, Umeda K, Arita Y, Mikami S, Fukumoto K, Yasumizu Y, Tanaka N, Takeda T, Morita S, Kosaka T, Mizuno R, Hara S, Oya M. Shigeta K, et al. Among authors: matsumoto k. Eur Urol Oncol. 2024 Feb 5:S2588-9311(24)00039-7. doi: 10.1016/j.euo.2024.01.013. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38320909 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

219 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

219 results

Results by year